New Evidence that HRSA in 2020 Declared Permanent a 340B Policy it Abruptly Ended Last Week

Correspondence
In a May 18, 2020, email exchange, a 340B prime vendor executive (bottom excerpt) confirmed to a lawyer representing a 340B hospital (top excerpt) that HRSA's policy about using 340B drugs in hospital sites not on the hospital's most recently filed cost report was "applicable regardless of COVID-19."

Correspondence in April and May 2020 between the 340B prime vendor and a law firm sheds more light on the start of a policy that the federal government ended abruptly last week that let hospitals start using 340B drugs at

Read More »

Breaking News

HRSA and Prime Vendor Yank FAQs About 340B Use in Hospital Child Sites, and GAO Issues a New 340B Study

FAQ excerpt
Excerpts from 340B FAQs that HRSA (top) and the 340B prime vendor Apexus (bottom) have removed from their websites.

The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about use of

Read More »

340B Did Not Arise in Senate Committee Today, But Might in House Subcommittee Next Week

Braun
Sen. Mike Braun (R-Ind.) did not offer a 340B covered entity transparency amendment to a PBM oversight bill during a Senate HELP hearing today. There was speculation that he might.

U.S. Sen. Mike Braun (R-Ind.) did not seek to amend a PBM oversight bill that is being marked up today to require 340B hospitals and possibly other covered entities to be more transparent about how they use money saved or

Read More »

Janssen to Pay Refunds for 340B Overcharges in Q2 2020

Janssen
Janssen Biotech is paying refunds for overcharges on certain 340B drugs purchased in the third quarter of 2020.

Drug manufacturer Janssen Pharmaceuticals said last week it would pay refunds for overcharges on 340B drugs purchased in the second quarter of 2020, including top-selling psoriasis drug Stelara.

Janssen, part of Johnson & Johnson, said it owes or may owe

Read More »

“This Is Bananas”: Hospitals Irate About HRSA’s Snap Decision to End 340B Patient Eligibility Clarification

Hospital outpatient location
340B hospitals expressed shock at HRSA's decision to cease a policy that has let patients receive 340B drugs at offsite outpatient locations that are sill going through the 340B registration process.

Editor’s note: New information from HRSA and Apexus obtained as we were going to press appears at the end of this article.

Hospital representatives said they were floored to learn yesterday that a June 2020 federal 340B patient eligibility policy

Read More »

U.S. House Panel Not Expected to Markup 340B Legislation at Hearing Next Week

House Energy & Commerce Committee
The U.S. House Energy & Commerce health subcommittee is not expected to move any 340B legislation in May, sources say.

A U.S. House Energy & Commerce subcommittee plans next week to markup bills on transparency and competition in health care and send them to the full committee for votes before Memorial Day. Although its Republican vice chair’s draft 340B bill

Read More »

Lifestar, Chartwell Announce Refunds for Q4 2022 340B Overcharges

340B refund notices
HRSA recently posted notices on its website of refunds for 340B overcharges from two generic drug manufacturers.

Generic drug manufacturers Lifestar Pharma and Chartwell Pharmaceuticals may owe refunds to 340B covered entities for overcharges on drugs purchased from the companies in the fourth quarter of 2022, according to recent notices posted on the U.S. Health Resources and

Read More »

Exclusive

HRSA Says COVID Flexibility About Dispensing 340B Drugs in Unregistered Hospital Offsite Locations Will End Thursday

COVID-19 flexibility
HRSA has reversed course and will end a 340B COVID-19 flexibility that it previously said was permanent that lets hospitals under certain conditions start using 340B drugs at offsite outpatient locations sooner than HRSA would normally allow.

The U.S. Health Resources and Services Administration said late Friday that when the COVID-19 public health emergency ends on Thursday, so too will a nearly three-year-old policy clarification that lets hospitals under certain conditions dispense 340B drugs at offsite outpatient

Read More »

In Shift, 340B Health and AHA Now Say They Back Congressional Action on 340B Contract Pharmacy

Doris Matsui
340B Health and the AHA say they support 340B contract pharmacy legislation that Rep. Doris Matsui (D-Calif.) is working on.

Hospital group 340B Health and the American Hospital Association both have decided to support federal legislation to prohibit drug manufacturer restrictions on 340B covered entities’ use of contract pharmacies. A senior AHA official was quoted in a news article just

Read More »

Ex-GOP Congressman Burton Slams Current GOP Rep. Rosendale’s 340B Bill

Dan Burton
Retired U.S. Rep. Dan Burton (R-Ind.) lauded the 340B program and criticized a current GOP congressman's 340B bill in a newspaper op-ed this week.

Former Republican Congressman Dan Burton (Ind.) called the 340B program “a win for all parties involved” in a Kokomo, Indiana newspaper op-ed this week and said a current House Republican’s 340B bill could deny vulnerable Hoosiers access to care.

Rep.

Read More »
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live